Physician profile
Michelle Yu
NPI 1033605977
$957.53
in general payments reported to CMS, 2019-2025
11 companies · $54.48 in 2025
The $54.48 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $467 · 2022: $229 · 2023: $152 · 2024: $54.23 · 2025: $54.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $261.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $347.49 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $119.74 | 2021 | |
| Esperion Therapeutics, INC. | $115.67 | 2022 | |
| Mirati Therapeutics, INC. | $108.42 | 2023 | Krazati |
| Astrazeneca Pharmaceuticals LP | $98.50 | 2022 | |
| Ethicon US, LLC | $54.48 | 2025 | Enseal |
| Bluewind Medical | $30.80 | 2024 | Revi |
| Sk Life Science, INC. | $26.77 | 2023 | |
| Astellas Pharma US INC | $23.43 | 2024 | Cresemba |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.12 | 2023 | Xifaxan |
| Amgen INC. | $15.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.